Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: A randomized, two-period, crossover study
- 1 August 2021
- journal article
- research article
- Published by Dustri-Verlgag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 59 (08), 578-584
- https://doi.org/10.5414/cp203864
Abstract
Objective: Clozapine is the most effective therapy for schizophrenia. This study compared the bioequivalence of a generic formulation of clozapine (ChangZhou Pharmaceutical Factory Co. Ltd. Jiangsu, China) to the brand name formulation (Clozaril, HLS Therapeutics, Inc., Philadelphia, PA, USA) after multiple doses in Chinese schizophrenic patients. Materials and methods: This was a randomized, open-label, multiple-dose, 2-way crossover study in which patients with schizophrenia received the generic clozapine or Clozaril 100 mg twice daily for 10 days before crossing over to the alternate formulation for the next 10 days. Blood samples were collected at regular intervals during each treatment period, and plasma concentration of clozapine was determined by high-performance liquid chromatography. Results: 26 patients were enrolled, of whom 24 completed the study and were included in the steady-state analyses. The mean AUC(0-12) was 6,003.29 hxng/mL for generic clozapine and 6,347.53 hxng/mL for Clozaril. The mean C-max,C-ss was 698.52 ng/mL for generic clozapine and 739.75 ng/mL for Clozaril. The ratio of the adjusted geometric means and its 90% CI of the ratios for AUC(0-12) was 96.24% (89.60 - 103.36%), and for C-max,C-ss was 95.90% (88.91 - 103.44%). A total of 66 adverse events were reported by 22 (84.62%) subjects. Among them, 34 occurred in 17 (65.38%) patients during dosing of generic clozapine, and 32 occurred in 16 (61.54%) patients during dosing of brand-name clozapine. Conclusion: The result demonstrated that the generic clozapine was bioequivalent to brand-name clozapine (Clozaril). This would provide physicians with reassurance that patients who receive the studied generic clozapine will achieve similar plasma drug concentrations to those of brand-name clozapine (Clozaril).Keywords
This publication has 13 references indexed in Scilit:
- Bioequivalence of Generic and Brand Name Clozapine in Korean Schizophrenic Patients: A Randomized, Two-Period, Crossover StudyPsychiatry Investigation, 2015
- Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapineBMJ Open, 2014
- Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophreniaInternational Clinical Psychopharmacology, 2013
- Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996–2010Human Psychopharmacology: Clinical and Experimental, 2012
- Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomesBritish Journal of Clinical Pharmacology, 2011
- Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for PsychopharmacologyJournal of Psychopharmacology, 2011
- Switching from Brand‐Name to Generic Psychotropic Medications: A Literature ReviewCNS Neuroscience & Therapeutics, 2010
- ABCB1 and Cytochrome P450 PolymorphismsJournal of Clinical Psychopharmacology, 2009
- Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphismsPharmacogenomics, 2008
- Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine ConcentrationsJournal of Clinical Psychopharmacology, 2004